Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 37Breast Neoplasms 23Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 14Multiple Myeloma 14Neoplasm Metastasis 13Recurrence 10Melanoma 10Leukemia, Myeloid, Acute 10Colorectal Neoplasms 10Carcinoma, Renal Cell 10Lymphoma, Non-Hodgkin 9Leukemia, Lymphocytic, Chronic, B-Cell 9Urinary Bladder Neoplasms 8Lymphoma, Follicular 8Thyroid Neoplasms 7Hematologic Neoplasms 7Stomach Neoplasms 6Small Cell Lung Carcinoma 6Sarcoma 6Prostatic Neoplasms 6Ovarian Neoplasms 6Lymphoma, Mantle-Cell 6Lymphoma, B-Cell, Marginal Zone 6Lymphoma 6Lung Neoplasms 6Head and Neck Neoplasms 6Colonic Neoplasms 6Uterine Cervical Neoplasms 5Thyroid Cancer, Papillary 5

Interventions

nilotinib 1bosutinib 1asciminib 1Imatinib Mesylate 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Philadelphia Chromosome × 1 year × Clear all
NCT04971226 2026-06-05

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡